Search results
Results from the WOW.Com Content Network
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [ 8 ]
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [58] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [23]
Ensitrelvir has been studied for its potential use as post-exposure prophylaxis against COVID-19 in a phase 3 clinical trial. [3] [4] [5] Top-line results from this trial suggested that use of ensitrelvir as post-exposure prophylaxis may significantly reduce the risk of symptomatic COVID-19 infection in exposed household contacts compared to ...
SARS-CoV-2, the virus that causes COVID-19, has also been detected in plaques that form in arteries that may rupture and cause heart attacks and stroke in those infected with the virus.
This registry based, multi-center, multi-country data provide provisional support for the use of ECMO for COVID-19 associated acute hypoxemic respiratory failure. Given that this is a complex technology that can be resource intense, guidelines exist for the use of ECMO during the COVID-19 pandemic. [85] [86] [87]
Getting COVID-19 increases a person’s risk of having a heart attack or stroke at the same rate as developing heart disease, a new study published in Arteriosclerosis, Thrombosis and Vascular ...
The EMA also initiated an assessment for all COVID‑19 vaccines used in the EU for immune thrombocytopenia (ITP), described as low blood platelet levels that could lead to bruising and bleeding, as a possible side effect, whilst also stating that up to this point no link with any COVID‑19 had been established. [12]
Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics have initiated the Phase 3 MOVe-AHEAD trial to evaluate molnupiravir, an investigational oral antiviral therapeutic, for the prevention of ...